Holen Sie sich die Stockscreener-App
1.105
8.33%
0.085
Vorhandelsmarkt:
1.08
-0.025
-2.26%
Schlusskurs vom Vortag:
$1.02
Offen:
$1
24-Stunden-Volumen:
770.13K
Relative Volume:
0.29
Marktkapitalisierung:
$74.86M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-46.12M
KGV:
-1.2786
EPS:
-0.8642
Netto-Cashflow:
$-41.02M
1W Leistung:
-7.14%
1M Leistung:
-12.99%
6M Leistung:
+30.00%
1J Leistung:
-53.38%
1-Tages-Spanne:
$0.99
$1.11
1-Wochen-Bereich:
$0.9201
$1.28
52-Wochen-Spanne:
$0.7113
$2.815
Inflarx N V Stock (IFRX) Company Profile
Vergleichen Sie IFRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
1.105 | 69.10M | 0 | -46.12M | -41.02M | -0.8642 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-09-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-29 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-02-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-10-28 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-06 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-04-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-05 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-06-05 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | Herabstufung | SunTrust | Buy → Hold |
| 2019-01-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-10 | Eingeleitet | Credit Suisse | Outperform |
| 2018-07-13 | Eingeleitet | BMO Capital Markets | Outperform |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-28 | Eingeleitet | SunTrust | Buy |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Inflarx N V Aktie (IFRX) Neueste Nachrichten
InflaRx (NASDAQ:IFRX) Stock Rating Lowered by Leerink Partnrs - Defense World
Will InflaRx N.V. stock outperform Nasdaq indexJuly 2025 Update & Community Supported Trade Ideas - Newser
Is InflaRx N.V. (IF0) stock testing key supportWeekly Market Report & Risk Controlled Swing Alerts - Newser
InflaRx (IFRX) Downgraded by Leerink Partners with Lowered Price Target | IFRX Stock News - GuruFocus
Leerink Partners downgrades Inflarx stock rating to Market Perform on financing concerns - Investing.com Nigeria
Leerink Partners Downgrades InflaRx to Market Perform From Outperform, Adjusts PT to $2 From $5 - marketscreener.com
InflaRx N.V. (IFRX) 5.6% in After-hours: What’s Driving the Move? - Stocks Telegraph
Will InflaRx N.V. (IF0) stock deliver compounding returns2025 Investor Takeaways & Capital Efficiency Focused Strategies - Newser
How InflaRx N.V. (IF0) stock moves in volatile trading sessions2025 Price Action Summary & Safe Entry Trade Reports - Newser
Is InflaRx N.V. (IF0) stock supported by strong fundamentalsStop Loss & Verified Short-Term Trading Plans - Newser
What margin trends mean for InflaRx N.V. stock2025 Market Outlook & AI Forecasted Entry/Exit Points - Newser
Inflarx flexes; HS, CSU continue to percolate - BioWorld MedTech
Ready to Jump After Recent Trade: InflaRx N.V (IFRX) - Setenews
Cash per share of InflaRx N.V. – BER:IF0 - TradingView
InflaRx N.V. (NASDAQ:IFRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Can InflaRx N.V. (IF0) stock surprise with quarterly results2025 Trade Ideas & Weekly Watchlist for Hot Stocks - newser.com
Will InflaRx N.V. stock deliver strong dividend growthGold Moves & AI Enhanced Trading Signals - newser.com
Is InflaRx N.V. stock attractive for income investorsEarnings Risk Report & Stepwise Trade Execution Plans - newser.com
Can InflaRx N.V. stock sustain market leadershipWeekly Trend Recap & AI Driven Price Predictions - newser.com
InflaRx N.V. stock prediction for this weekMarket Rally & AI Driven Price Predictions - newser.com
Is InflaRx N.V. (IF0) stock cheap vs fundamentalsJuly 2025 Snapshot & Reliable Entry Point Trade Alerts - newser.com
InflaRx Stock: Gohibic Flops, INF904 Underwhelms, Cash Burn Accelerates (NASDAQ:IFRX) - Seeking Alpha
Can InflaRx N.V. recover in the next quarter2025 Stock Rankings & Technical Pattern Based Signals - newser.com
Will InflaRx N.V. (IF0) stock maintain strong growthMarket Growth Review & Low Risk High Reward Ideas - newser.com
Why InflaRx N.V. stock is considered a top pickMarket Growth Summary & AI Driven Stock Price Forecasts - newser.com
Volatility clustering patterns for InflaRx N.V.Entry Point & Risk Managed Investment Signals - newser.com
Finanzdaten der Inflarx N V-Aktie (IFRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):